semaglutide for alzheimer's Details of failed studies cast pall on Novo Nordisk's GLP-1 as treatment Novo Nordisk's oral GLP-1 drug

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, confirms that not all sources of semaglutide meet safety standards

Science Says As body weight decreases, the likelihood of developing a chronic illness drops significantly with one report seeing significantly fewer cases of kidney failure and cardiovascular disease for people with type 2 diabetes

F., Rocha, R

Vit D levels have shown to consistently be inversely associated with motor symptoms severity, however, this may very well be limited exposure to Vit D due to limited mobility (Fullard and Duda 2020)

Existing therapeutic strategies mainly focus on regulating homocysteine levels, with limited effective interventions targeting methionine itself